A commentary on ‘The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs’. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.